RUNX1 and myeloid sarcoma: Untaaveesup et al. evaluated 37 studies encompassing 5646 patients across pediatric and adult populations to characterize the prevalence of genetic alterations in MS, identifying FLT3-ITD as the most common mutation (17.5%) and RUNX1::RUNX1T1 as the most frequent fusion (28.5%), with NPM1 detected in 17% of MS patients [114].